Endo, BioDelivery painkiller effective in late-stage study
July 7 (Reuters) - Endo International Plc and BioDelivery Sciences International Inc said their experimental pain drug was found effective in a late-stage trial.
The painkiller, BEMA buprenorphine, was being tested against a placebo in patients with pain severe enough to require around-the-clock, long-term opioid treatment.
Opioids are a class of drugs that includes not only powerful prescription painkillers like morphine, oxycodone and fentanyl but also heroin. (Reporting by Natalie Grover in Bangalore; Editing by Saumyadeb Chakrabarty)
- Washington wins diplomatic support for campaign in Iraq; Syria trickier |
- Apple iPhone 6 pre-orders hit record 4 million on first day |
- Western sanctions are testing Russia's strength: Medvedev |
- Alibaba worried about Facebook IPO as considered Nasdaq versus NYSE |
- Exclusive: Two Apple medical trials shed light on how HealthKit will work